Pemafibrate low dose

Phase 2Small molecule

Pemafibrate low dose is one of 45 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Amitiza

SSucampo Pharma Americas, LLC

Phase 3

1 3

Rezdiffra

Madrigal Pharmaceuticals

Phase 3

1 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Farxiga

AstraZeneca

Phase 2

4 6

Ozempic

Novo Nordisk

Phase 2

1 7

Bayer Aspirin

Bayer

Phase 2

1 8

Lipaglyn

ZZydus Therapeutics Inc.

Phase 2

6 9

Combination Drug

Bayer

Phase 3

1 10

Efruxifermin

Akero Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcoholic Fatty Liver Disease1 trial

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

Active, not recruiting·YYokohama City University·Phase 2·NCT06623539·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pemafibrate low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemafibrate low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemafibrate low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yokohama City University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYokohama City University

Pemafibrate low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News